Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the ...

Eli Lilly investors and analysts said they want ... citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi ...

making it one of the most extensive so far on a class of medicines that includes Novo Nordisk’s Wegovy and Eli Lilly & Co’s Zepbound. The study, published on Jan 20 in the journal Nature ...

Learn More » Pfizer (NYSE: PFE) stood out a few years ago thanks to its coronavirus products and a portfolio of ... looks like a great bargain that value investors won't want to miss. Eli Lilly (NYSE: ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... and experimental drugs for COVID-19. “The bottom line: Ask yourself what happens if things get better ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, but growth may accelerate after 2026. Read more here.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

UnitedHealth Group CEO says complex US healthcare system needs to change Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall ...

This potential aside, the sector has largely been beaten up post-COVID-19. The S&P 500 Health Care ... Even share prices of GLP-1 drug makers Eli Lilly and Co. LLY-N, behind Zepbound, and Novo ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...